Merus NV
General ticker "MRUS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.0B
Merus NV follows the US Stock Market performance with the rate: 41.9%.
Estimated limits based on current volatility of 2.2%: low 41.80$, high 43.67$
Factors to consider:
- Current price 17.7% above estimated high
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [18.10$, 36.08$]
- 2024-12-30 to 2025-12-30 estimated range: [19.63$, 38.09$]
Financial Metrics affecting the MRUS estimates:
- Negative: Non-GAAP EPS, $ of -3.04 <= 0.10
- Negative: Operating profit margin, % of -78.08 <= 1.03
- Negative: Operating cash flow per share per price, % of -9.96 <= 2.35
- Negative: negative Net income
- Positive: -0.96 < Investing cash flow per share, $ of -0.52
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Positive: Inventory ratio change, % of -1.45 <= -1.03
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
Short-term MRUS quotes
Long-term MRUS plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $49.11MM | $41.59MM | $43.95MM |
| Operating Expenses | $139.08MM | $201.62MM | $200.49MM |
| Operating Income | $-89.98MM | $-160.04MM | $-156.55MM |
| Non-Operating Income | $23.40MM | $29.80MM | $4.80MM |
| Interest Expense | $0.13MM | $2.72MM | $0.00MM |
| R&D Expense | $98.19MM | $149.42MM | $140.66MM |
| Income(Loss) | $-66.58MM | $-130.24MM | $-151.75MM |
| Taxes | $0.24MM | $0.96MM | $3.19MM |
| Profit(Loss) | $-66.82MM | $-131.19MM | $-154.94MM |
| Stockholders Equity | $316.20MM | $247.06MM | $356.34MM |
| Inventory | $4.91MM | $9.31MM | $0.00MM |
| Assets | $456.60MM | $376.54MM | $455.49MM |
| Operating Cash Flow | $-59.63MM | $-149.90MM | $-142.21MM |
| Capital expenditure | $0.87MM | $7.64MM | $3.98MM |
| Investing Cash Flow | $-146.62MM | $2.80MM | $-27.02MM |
| Financing Cash Flow | $281.95MM | $58.74MM | $230.09MM |
| Earnings Per Share* | $-1.73 | $-2.92 | $-3.00 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.